Rhumbline Advisers Eagle Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$3.34 - $5.6 $33,132 - $55,552	-9,920 Reduced 57.79%	7,246 $40,000
Q1 2024 May 09, 2024	SELL	$4.26 - $6.51 $745 - $1,139	-175 Reduced 1.01%	17,166 $89,000
Q4 2023 Feb 08, 2024	BUY	$4.63 - $15.21 $967 - $3,178	209 Added 1.22%	17,341 $90,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $471 - $709	-31 Reduced 0.18%	17,132 $270,000
Q2 2023 Aug 08, 2023	SELL	$17.74 - $31.87 $257,673 - $462,911	-14,525 Reduced 45.84%	17,163 $333,000
Q1 2023 May 11, 2023	BUY	$25.06 - $34.09 $39,118 - $53,214	1,561 Added 5.18%	31,688 $899,000
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $18,085 - $28,793	-724 Reduced 2.35%	30,127 $881,000
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $1,822 - $3,251	69 Added 0.22%	30,851 $815,000
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $92,628 - $115,280	-2,245 Reduced 6.8%	30,782 $1.37 Million
Q1 2022 May 12, 2022	BUY	$44.58 - $52.6 $39,453 - $46,551	885 Added 2.75%	33,027 $1.64 Million
Q4 2021 Feb 10, 2022	SELL	$45.82 - $56.9 $44,399 - $55,136	-969 Reduced 2.93%	32,142 $1.64 Million
Q3 2021 Nov 12, 2021	SELL	$43.79 - $55.78 $186,983 - $238,180	-4,270 Reduced 11.42%	33,111 $1.85 Million
Q2 2021 Aug 05, 2021	BUY	$36.86 - $44.5 $34,390 - $41,518	933 Added 2.56%	37,381 $1.6 Million
Q1 2021 May 06, 2021	BUY	$40.32 - $50.97 $57,335 - $72,479	1,422 Added 4.06%	36,448 $1.52 Million
Q4 2020 Feb 10, 2021	BUY	$41.72 - $51.34 $5,215 - $6,417	125 Added 0.36%	35,026 $1.63 Million
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $18,732 - $25,947	506 Added 1.47%	34,901 $1.48 Million
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $43,672 - $55,570	-1,010 Reduced 2.85%	34,395 $1.65 Million
Q1 2020 May 06, 2020	BUY	$34.37 - $60.07 $55,060 - $96,232	1,602 Added 4.74%	35,405 $1.63 Million
Q4 2019 Feb 05, 2020	BUY	$54.32 - $64.31 $82,349 - $97,493	1,516 Added 4.7%	33,803 $2.03 Million
Q3 2019 Oct 23, 2019	SELL	$53.25 - $59.98 $50,800 - $57,220	-954 Reduced 2.87%	32,287 $1.83 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $58,775 - $73,705	1,261 Added 3.94%	33,241 $1.85 Million
Q1 2019 May 01, 2019	SELL	$38.66 - $51.82 $82,152 - $110,117	-2,125 Reduced 6.23%	31,980 $1.62 Million
Q4 2018 Jan 31, 2019	BUY	$36.72 - $67.73 $280,430 - $517,254	7,637 Added 28.85%	34,105 $1.37 Million
Q3 2018 Nov 07, 2018	BUY	$66.65 - $83.86 $136,032 - $171,158	2,041 Added 8.36%	26,468 $1.84 Million
Q2 2018 Aug 06, 2018	BUY	$51.25 - $76.62 $230,522 - $344,636	4,498 Added 22.57%	24,427 $1.85 Million
Q1 2018 May 02, 2018	BUY	$52.16 - $66.86 $22,324 - $28,616	428 Added 2.19%	19,929 $1.05 Million
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $120,280 - $147,609	2,425 Added 14.2%	19,501 $1.04 Million
Q3 2017 Nov 06, 2017	BUY	$46.62 - $60.36 $796,083 - $1.03 Million	17,076	17,076 $1.02 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account